Covered recipient · General Payments record
LILLIAN FRANCES LIEN
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2024
$3,665.41
- Reported across 163 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $328.12 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| DEXCOM, INC. | $83.32 | 3 |
| Amgen Inc. | $68.43 | 3 |
| SANOFI-AVENTIS U.S. LLC | $45.75 | 2 |
| Xeris Pharmaceuticals, Inc. | $37.58 | 2 |
| Lilly USA, LLC | $33.06 | 2 |
| Kyowa Kirin, Inc. | $21.41 | 1 |
| Insulet Corporation | $21.40 | 1 |
| Abbott Laboratories | $17.17 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $17.17 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124805682 | CMS |
| Amgen Inc. | $20.53 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111634826 | CMS |
| Amgen Inc. | $29.63 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111634828 | CMS |
| Amgen Inc. | $18.27 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111634830 | CMS |
| Dexcom, Inc. | $30.75 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153316804 | CMS |
| Dexcom, Inc. | $30.36 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153316806 | CMS |
| Dexcom, Inc. | $22.21 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153316808 | CMS |
| Insulet Corporation | $21.40 | 05/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116805338 | CMS |
| Kyowa Kirin, Inc. | $21.41 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127035748 | CMS |
| Lilly USA, LLC | $19.56 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135141285 | CMS |
| Lilly USA, LLC | $13.50 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135142403 | CMS |
| SANOFI-AVENTIS U.S. LLC | $23.78 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139679215 | CMS |
| SANOFI-AVENTIS U.S. LLC | $21.97 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139679245 | CMS |
| Xeris Pharmaceuticals, Inc. | $16.67 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144602827 | CMS |
| Xeris Pharmaceuticals, Inc. | $20.91 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144602825 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.